# Deucrictibant PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/deucrictibant

> The PDUFA target action date for deucrictibant, sponsored by Pharvaris N.V. (PHVS), is April 23, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the deucrictibant PDUFA date?

The PDUFA target action date for deucrictibant, sponsored by Pharvaris N.V. (PHVS), is April 23, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027" Last confirmed November 12, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/deucrictibant)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-456847, https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/pdufa/deucrictibant#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | deucrictibant |
| Codes | PHA121 |
| Sponsor | Pharvaris N.V. (PHVS) https://sec-api.dev/companies/phvs/catalysts |
| Indications | aae-c1inh attacks, hae attacks, hae in december 2022 |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Feb 2021: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: HAE in December 2022.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126327): "We commenced our RAPIDe-1 Phase 2 clinical trial of deucrictibant in February 2021 and reported topline Phase 2 data for the on-demand treatment of attacks in people with HAE in December 2022." https://www.sec.gov/Archives/edgar/data/1830487/000095017024126327/phvs-ex99_2.htm

### Dec 2022: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-04-07, last confirmed 2025-06-10.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-084094): "In December 2022, we announced positive top-line data from RAPIDe-1, a Phase 2, double-blind, placebo-controlled, randomized, crossover, dose-ranging study of deucrictibant IR capsule for the on-demand treatment of HAE type 1 and type 2 (HAE-1/2) attacks." https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm
- SEC Form 10-K (accession 0000950170-25-051347): "In December 2022, we announced positive top-line data from RAPIDe-1, a Phase 2, double-blind, placebo-controlled, randomized, crossover, dose-ranging study of deucrictibant IR capsule for the on-demand treatment of HAE type 1 and type 2 (HAE-1/2) attacks." https://www.sec.gov/Archives/edgar/data/1830487/000095017025051347/phvs-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-084094): "We commenced RAPIDe-1 in February 2021 and reported positive topline Phase 2 data in December 2022." https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm
- SEC Form 10-K (accession 0000950170-25-051347): "We commenced RAPIDe-1 in February 2021 and reported positive topline Phase 2 data in December 2022." https://www.sec.gov/Archives/edgar/data/1830487/000095017025051347/phvs-20241231.htm

### Dec 2023: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126327): "We commenced this CHAPTER-1 Phase 2 clinical trial in 2021 using twice-daily dosing of the deucrictibant immediate-release capsules as a proof-of-concept and announced positive topline data in December 2023." https://www.sec.gov/Archives/edgar/data/1830487/000095017024126327/phvs-ex99_2.htm

### Dec 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2024-11-13, last confirmed 2026-06-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276005): "A Phase 2 placebo-controlled trial evaluating the efficacy and the safety and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and 2 (CHAPTER-1) commenced in 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023, demonstrating the clinical efficacy and tolerability of deucrictibant." https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-107316): "A Phase 2 placebo-controlled trial evaluating the efficacy and the safety and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and 2 (CHAPTER-1) commenced in 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023, demonstrating the clinical efficacy and tolerability of deucrictibant." https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-084094): "A Phase 2 placebo-controlled trial evaluating the efficacy and the safety and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and 2 (CHAPTER-1) commenced CHAPTER-1 in 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023, demonstrating the clinical efficacy and tolerability of deucrictibant." https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-070308): "A Phase 2 placebo-controlled trial evaluating the efficacy and the safety and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and 2 (CHAPTER-1) commenced CHAPTER-1 in 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023, demonstrating the clinical efficacy and tolerability of deucrictibant." https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126327): "We commenced this CHAPTER-1 Phase 2 clinical trial in 2021 using twice-daily dosing of the deucrictibant immediate-release capsules as a proof-of-concept and announced positive topline data in December 2023." https://www.sec.gov/Archives/edgar/data/1830487/000095017024126327/phvs-ex99_2.htm
- SEC Form 10-K (accession 0000950170-25-051347): "A Phase 2 placebo-controlled trial evaluating the efficacy and the safety and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and 2 (CHAPTER-1) commenced CHAPTER-1 in 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023, demonstrating the clinical efficacy and tolerability of deucrictibant." https://www.sec.gov/Archives/edgar/data/1830487/000095017025051347/phvs-20241231.htm
- SEC prospectus (424B) (accession 0001193125-25-163778): "A Phase 2 placebo-controlled trial evaluating the efficacy and the safety and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and 2 (CHAPTER-1) commenced CHAPTER-1 in 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023, demonstrating the clinical efficacy and tolerability of deucrictibant." https://www.sec.gov/Archives/edgar/data/1830487/000119312525163778/d932470d424b5.htm
- SEC prospectus (424B) (accession 0001193125-25-162585): "A Phase 2 placebo-controlled trial evaluating the efficacy and the safety and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and 2 (CHAPTER-1) commenced CHAPTER-1 in 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023, demonstrating the clinical efficacy and tolerability of deucrictibant." https://www.sec.gov/Archives/edgar/data/1830487/000119312525162585/d932470d424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-266666): "We commenced CHAPTER-1 in November 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023." https://www.sec.gov/Archives/edgar/data/1830487/000119312526266666/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-084094): "We commenced CHAPTER-1 in 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023." https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm
- SEC Form 10-K (accession 0001830487-26-000013): "We commenced CHAPTER-1 in November 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023." https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm
- SEC Form 10-K (accession 0000950170-25-051347): "We commenced CHAPTER-1 in 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023." https://www.sec.gov/Archives/edgar/data/1830487/000095017025051347/phvs-20241231.htm

### Mar 2024: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-04-07, last confirmed 2026-06-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-266666): "Following the readout of RAPIDe-2, we initiated RAPIDe-3, a global, pivotal Phase 3, placebo-controlled study to evaluate deucrictibant IR capsule (20 mg) for the on-demand treatment of attacks in people 12 years and older with HAE, in March 2024 and reported topline data in December 2025." https://www.sec.gov/Archives/edgar/data/1830487/000119312526266666/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-266666): "We initiated RAPIDe-3, a global, pivotal Phase 3, placebo-controlled study to evaluate deucrictibant IR capsule (20 mg) for the on-demand treatment of attacks in people 12 years and older with HAE, in March 2024 and reported topline data in December 2025." https://www.sec.gov/Archives/edgar/data/1830487/000119312526266666/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276005): "In March 2024, we initiated a global, pivotal, randomized, double-blind-placebo-controlled Phase 3 study, RAPIDe-3, of orally administered deucrictibant IR capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), and have enrolled approximately 120 participants." https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-107316): "In March 2024, we initiated a global, pivotal, randomized, double-blind-placebo-controlled Phase 3 study, RAPIDe-3, of orally administered deucrictibant IR capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), and have enrolled approximately 120" https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-084094): "In March 2024, we initiated a global, pivotal, randomized, double-blind-placebo-controlled Phase 3 study of orally administered deucrictibant IR capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older)." https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-084094): "In March 2024, Pharvaris initiated a global, pivotal, randomized, double-blind-placebo-controlled Phase 3 study of orally administered deucrictibant IR capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older)." https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-084094): "In March 2024, we initiated a global, pivotal, randomized, double-blind-placebo-controlled Phase 3 study, RAPIDe-3, of orally administered deucrictibant IR capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), and intend to enroll approximately 120 participants." https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-070308): "In March 2024, we initiated a global, pivotal, randomized, double-blind-placebo-controlled Phase 3 study, RAPIDe-3, of orally administered deucrictibant IR capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), and intend to enroll approximately 120 participants." https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_2.htm
- SEC Form 10-K (accession 0001830487-26-000013): "Following the readout of RAPIDe-2, we initiated RAPIDe-3, a global, pivotal Phase 3, placebo-controlled study to evaluate deucrictibant IR capsule (20 mg) for the on-demand treatment of attacks in people 12 years and older with HAE, in March 2024 and reported topline data in December 2025." https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm
- SEC Form 10-K (accession 0000950170-25-051347): "In March 2024, we initiated a global, pivotal, randomized, double-blind-placebo-controlled Phase 3 study of orally administered deucrictibant IR capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older)." https://www.sec.gov/Archives/edgar/data/1830487/000095017025051347/phvs-20241231.htm
- SEC Form 10-K (accession 0000950170-25-051347): "In March 2024, we initiated a global, pivotal, randomized, double-blind-placebo-controlled Phase 3 study, RAPIDe-3, of orally administered deucrictibant IR capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), and intend to enroll approximately 120 participants." https://www.sec.gov/Archives/edgar/data/1830487/000095017025051347/phvs-20241231.htm

### late 2024: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126327): "Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE by year-end 2024." https://www.sec.gov/Archives/edgar/data/1830487/000095017024126327/phvs-ex99_1.htm

### Dec 2024: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-04-07, last confirmed 2026-06-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-266666): "In December 2024, we initiated CHAPTER-3, a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." https://www.sec.gov/Archives/edgar/data/1830487/000119312526266666/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-266666): "In December 2024, Pharvaris initiated a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." https://www.sec.gov/Archives/edgar/data/1830487/000119312526266666/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276005): "In December 2024, we initiated a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study, CHAPTER-3, of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-107316): "In December 2024, we initiated a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study, CHAPTER-3, of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-084094): "In December 2024, we initiated a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-084094): "In December 2024, Pharvaris initiated a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-084094): "In December 2024, we initiated a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study, CHAPTER-3, of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-070308): "In December 2024, we initiated a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study, CHAPTER-3, of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_2.htm
- SEC Form 10-K (accession 0001830487-26-000013): "In December 2024, we initiated CHAPTER-3, a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm
- SEC Form 10-K (accession 0000950170-25-051347): "In December 2024, we initiated a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." https://www.sec.gov/Archives/edgar/data/1830487/000095017025051347/phvs-20241231.htm
- SEC Form 10-K (accession 0000950170-25-051347): "In December 2024, we initiated a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study, CHAPTER-3, of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." https://www.sec.gov/Archives/edgar/data/1830487/000095017025051347/phvs-20241231.htm

### Oct 2025: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-456847): "In October 2025, we initiated CREAATE, a global, pivotal Phase 3 study to assess the efficacy and safety of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks." https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-266666): "In October 2025, we initiated CREAATE, a global, pivotal Phase 3 study to assess the efficacy and safety of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks." https://www.sec.gov/Archives/edgar/data/1830487/000119312526266666/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-266666): "In October 2025, we initiated CREAATE, a global, pivotal Phase 3 study of to assess the efficacy and safety of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks." https://www.sec.gov/Archives/edgar/data/1830487/000119312526266666/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-009705): "Pharvaris initiated CREAATE, a global, pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks, in November 2025." https://www.sec.gov/Archives/edgar/data/1830487/000119312526009705/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276005): "In October 2025, we initiated a global, three-part, pivotal Phase 3 study, CREAATE, of deucrictibant for the prophylactic and on-demand treatment of adults (18 years and older) with AAE-C1INH." https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_2.htm
- SEC Form 10-K (accession 0001830487-26-000013): "In October 2025, we initiated CREAATE, a global, pivotal Phase 3 study to assess the efficacy and safety of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks." https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm
- SEC Form 10-K (accession 0001830487-26-000013): "In October 2025, we initiated CREAATE, a global, pivotal Phase 3 study of to assess the efficacy and safety of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks." https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-07-10, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276005): "Pharvaris expects to announce top-line data in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276005): "Topline data from RAPIDe-3 is anticipated in the fourth quarter of 2025 and, pending positive data, we expect to submit a New Drug Application with the FDA in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-107316): "Given the current dataset of evaluable attacks, Pharvaris anticipates announcing topline results in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-157363): "Pharvaris anticipates announcing topline data from RAPIDe-3 in the fourth quarter of 2025 and, pending positive data, expects to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1830487/000119312525157363/d17337dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276005): "Topline data from RAPIDe-3 (NCT06343779) expected in 4Q2025." https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-107316): "Topline results from RAPIDe-3 (NCT06343779) anticipated in 4Q2025." https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-107316): "Topline data from RAPIDe-3 is anticipated in the fourth quarter of 2025 and, pending positive data, we expect to submit a New Drug Application with the FDA in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-107316): ""The readout of RAPIDe-3 topline results, which is estimated to be in the fourth quarter of this year, is anticipated to be an important inflection point for our stakeholders." https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276005): "Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025" https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-107316): "Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025" https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-157363): "The attack data in RAPIDe-3 have continued to accrue following the achievement of target enrollment in the study; we now estimate that our RAPIDe-3 topline data announcement will be in the fourth quarter of this year, said Berndt Modig, Chief Executive Officer of Pharvaris. Our phase 3 data may provide evidence of deucrictibant IRs potential to address the desire of people living with HAE for an on-demand therapy that combines efficacyfrom rapid end of progression to fast and complete resolutionand a favorable safety profile, with the convenience of a single-capsule oral dose." https://www.sec.gov/Archives/edgar/data/1830487/000119312525157363/d17337dex991.htm

### 1H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-07-10, last confirmed 2026-06-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-157363): "Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026" https://www.sec.gov/Archives/edgar/data/1830487/000119312525157363/d17337dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001830487-26-000012): "With the momentum of this important milestone, we continue to execute in 2026 through the anticipated NDA submission of deucrictibant IR for the on-demand treatment of HAE attacks, topline data readout of CHAPTER-3, and enrollment in CREAATE," said Berndt Modig, Chief Executive Officer of Pharvaris." https://www.sec.gov/Archives/edgar/data/1830487/000183048726000012/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-266666): "Pharvaris plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute attacks of HAE." https://www.sec.gov/Archives/edgar/data/1830487/000119312526266666/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219372): "the timing and outcome of regulatory approvals, including the timing and outcome of our planned submission of an NDA with the FDA in the first half of 2026 for the on-demand treatment of acute attacks of HAE" https://www.sec.gov/Archives/edgar/data/1830487/000119312526219372/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001830487-26-000012): "the timing and outcome of regulatory approvals, including the timing and outcome of our planned submission of an NDA with the FDA in the first half of 2026 for the on-demand treatment of acute attacks of HAE" https://www.sec.gov/Archives/edgar/data/1830487/000183048726000012/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-009705): "the timing and outcome of regulatory approvals, including the timing and outcome of our planned submission of an NDA with the FDA in the first half of 2026 for the on-demand treatment of acute attacks of HAE" https://www.sec.gov/Archives/edgar/data/1830487/000119312526009705/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276005): "Topline data from RAPIDe-3 is anticipated in the fourth quarter of 2025 and, pending positive data, we expect to submit a New Drug Application with the FDA in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-157363): "Pharvaris anticipates announcing topline data from RAPIDe-3 in the fourth quarter of 2025 and, pending positive data, expects to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1830487/000119312525157363/d17337dex991.htm

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: HAE attacks.
- First seen 2025-01-13, last confirmed 2025-06-10.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-084094): "Topline data from RAPIDe-3 is anticipated in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-070308): "Topline data from RAPIDe-3 is anticipated in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-004542): "Pharvaris anticipates announcing topline data of RAPIDe-3 in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1830487/000095017025004542/phvs-ex99_1.htm
- SEC Form 10-K (accession 0000950170-25-051347): "Topline data from RAPIDe-3 is anticipated in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1830487/000095017025051347/phvs-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-004542): "Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026" https://www.sec.gov/Archives/edgar/data/1830487/000095017025004542/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-004542): "Topline data from RAPIDe-3 (NCT06343779), a global Phase 3 study evaluating deucrictibant for the treatment of HAE attacks, anticipated 1Q2026." https://www.sec.gov/Archives/edgar/data/1830487/000095017025004542/phvs-ex99_1.htm

### Q3 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-01-13, last confirmed 2026-08-12.
- Press release filed with the SEC (EX-99) (accession 0001830487-26-000012): "Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026" https://www.sec.gov/Archives/edgar/data/1830487/000183048726000012/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-009705): "Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026" https://www.sec.gov/Archives/edgar/data/1830487/000119312526009705/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-345702): "Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026" https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219372): "Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026" https://www.sec.gov/Archives/edgar/data/1830487/000119312526219372/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276005): "Enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release tablet for prophylaxis of HAE attacks, is progressing as planned; topline data anticipated in 2H2026" https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-107316): "Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026" https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-070308): "Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026" https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-051348): "Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026" https://www.sec.gov/Archives/edgar/data/1830487/000095017025051348/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-004542): "Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026" https://www.sec.gov/Archives/edgar/data/1830487/000095017025004542/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-004542): "Initiated CHAPTER-3 (NCT06669754), a global pivotal Phase 3 study, evaluating deucrictibant for the prophylactic treatment of HAE attacks; topline data anticipated 2H2026." https://www.sec.gov/Archives/edgar/data/1830487/000095017025004542/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-009705): "Our team's ability to conduct the most diverse Phase 3 on-demand study in HAE, by including previously underserved regions and subgroups, and improve upon the outcomes of the RAPIDe-1 Phase 2 study further bolsters our confidence in the clinical execution of the CHAPTER-3 prophylactic study, for which the timing of anticipated data readout has now been refined to the third quarter of 2026."" https://www.sec.gov/Archives/edgar/data/1830487/000119312526009705/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001830487-26-000012): "With the momentum of this important milestone, we continue to execute in 2026 through the anticipated NDA submission of deucrictibant IR for the on-demand treatment of HAE attacks, topline data readout of CHAPTER-3, and enrollment in CREAATE," said Berndt Modig, Chief Executive Officer of Pharvaris." https://www.sec.gov/Archives/edgar/data/1830487/000183048726000012/phvs-ex99_1.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: AAE-C1INH attacks.
- First seen 2026-09-08, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-456847): "Topline data from part 1 of CREAATE (NCT07266805) expected in 1Q2027." https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-456847): "Pharvaris expects to announce topline data from part 1 of CREAATE in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-456847): "We expect to report topline data from part 1 of this study in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-456847): "Topline data from part 1 of CREAATE, a pivotal Phase 3 study evaluating deucrictibant XR for the prophylaxis of AAE-C1INH attacks, expected in 1Q2027; enrollment ongoing in part 2 of CREAATE evaluating deucrictibant IR for the on-demand treatment of AAE-C1INH attacks" https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-384339): "Topline data from Part 1 of CREAATE (NCT07266805), a global, pivotal Phase 3 study evaluating orally-administered deucrictibant XR for the prevention of AAE-C1INH attacks, are anticipated in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1830487/000119312526384339/phvs-ex99_1.htm

### 1H 2027: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-456847): "We plan to submit an NDA for deucrictibant XR for the prevention of AE-BK attacks with the FDA in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm

### April 23, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-08-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-456847): "Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027" https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-345702): "Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA validated by the EMA in July 2026" https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-384472): "PDUFA: April 23, 2027 NDA Submission: 1H2027 Part 1 Topline Data: 1Q2027" https://www.sec.gov/Archives/edgar/data/1830487/000119312526384472/phvs-ex99_1.htm

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/deucrictibant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Deucrictibant PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/deucrictibant

```bibtex
@misc{secapidev_pdufa_deucrictibant_20261116,
  title        = {Deucrictibant PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/deucrictibant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_deucrictibant_20261116","title":"Deucrictibant PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/deucrictibant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
